Maxim Affirms Inovio Pharma (INO) at 'Buy' as INO-8000 Phase 1 in HCV Begins; Cost Remains Key Factor

Maxim affirmed Inovio Pharmaceuticals (Nasdaq: INO) with a Buy rating and $14 price target as Inovio announced that its immunotherapy for hepatitis C (INO-8000) will be evaluated in a phase I trial in chronically infected patients who are not receiving other hepatitis C virus (HCV) treatments.

Analyst Jason McCarthy commented on the news: While the HCV space has been dominated by blockbuster antivirals like Harvoni and Sovaldi that are essentially a cure, their high cost is and will likely remain a factor that limits access to many patients. A more cost effective alternative (or in addition to antiviral therapy) would be a vaccine approach like INO-8000, which beyond initial viral elimination would also induce immune memory, potentially guarding against re-infection.

For an analyst ratings summary and ratings history on Inovio Pharmaceuticals click here. For more ratings news on Inovio Pharmaceuticals click here.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Inovio Pharma (INO) Prices $36M Share and Warrant Offering at $7.69/sh
• Piper Sandler Downgrades Southwestern Energy (SWN) to Neutral